IP Library › Granted Patent US 12,053,438
Granted Patent B2
US 12,053,438 · App. 17/002,568 · Granted Aug 6, 2024

Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof

Inventor: Benny Antony (Ankamaly, IN)
Assignee: ARJUNA NATURAL PRIVATE LIMITED
A61K31/12A61K36/9066
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,053,438
App. No.
17/002,568
Granted
Aug 6, 2024
Kind
B2
Abstract

A formulation of curcuminoid mixture having curcumin, demethoxycurcumin and bisdemethoxycurcumin and an essential oil of turmeric having 45% Ar-turmerone. The formulation gives enhanced bioavailability of bisdemethoxycurcumin, demethoxycurcumin and curcumin for up to 10 hrs. The curcuminoid mixture has curcumin, demethoxycurcumin and bisdemethoxycurcumin in a weight/weight ratio ranging from about 0.8:1:1 to about 1:1.1:1.2. A process of preparing a formulation of curcuminoid mixture having curcumin, demethoxycurcumin and bisdemethoxycurcumin in 0.8:1:1 to 1:1.1:1.2 weight/weight ratio and an essential oil of turmeric having 45% Ar-turmerone. A formulation for improved biological activity and bioavailability and tissue distribution of curcumin, demethoxycurcumin and bisdemethoxycurcumin.

Claims (8)

1. A method of decreasing inflammation comprising administering a composition for enhanced bioavailability of curcumin, demethoxycurcumin and bisdemethoxycurcumin, the composition comprising a curcuminoid mixture and essential oil of turmeric, wherein the curcuminoid mixture comprises curcumin, demethoxycurcumin and bisdemethoxycurcumin in a weight ratio of curcumin:demethoxycurcumin:bisdemethoxycurcumin of about 0.8:1:1 to about 1:1.1:1.2, wherein the essential oil of turmeric comprises about 45% Ar-turmerone, and, wherein a weight ratio of the curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1.

2. The method of decreasing inflammation of claim 1 , wherein the weight ratio of the curcuminoid mixture to essential oil of turmeric is about 12:1.

3. The method of decreasing inflammation of claim 1 , wherein the weight ratio of the curcuminoid mixture to essential oil of turmeric is about 10:1.

4. The method of decreasing inflammation of claim 1 , wherein a decrease in inflammation is observed from about 30 mins to about 24 hours.

5. A method of enhancing bioavailability of curcumin, demethoxycurcumin and bisdemethoxycurcumin comprising administering a composition for enhanced bioavailability of curcumin, demethoxycurcumin and bisdemethoxycurcumin, the composition comprising a curcuminoid mixture and essential oil of turmeric, wherein the curcuminoid mixture comprises curcumin, demethoxycurcumin and bisdemethoxycurcumin in a weight ratio of curcumin:demethoxycurcumin:bisdemethoxycurcumin of about 0.8:1:1 to about 1:1.1:1.2, and the essential oil of turmeric comprises about 45% Ar-turmerone, and, wherein a weight ratio of the curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1.

6. The method of enhancing bioavailability of curcumin, dimethoxycurcumin and bisdemethoxycurcumin of claim 5 , wherein the weight ratio of the curcuminoid mixture to essential oil of turmeric is about 12:1.

7. The method of enhancing bioavailability of curcumin, dimethoxycurcumin and bisdemethoxycurcumin of claim 5 , wherein the weight ratio of the curcuminoid mixture to essential oil of turmeric is about 10:1.

8. The method of enhancing bioavailability of curcumin, dimethoxycurcumin and bisdemethoxycurcumin of claim 5 , wherein an enhancement of bioavailability of curcumin, dimethoxycurcumin and bisdemethoxycurcumin is observed in a tissue, and wherein the tissue is selected from the group consisting of lungs, heart, kidney, brain, liver, pancreas, stomach, intestine and skin.

Priority Claims (3)
IN 950CHE2010 · Apr 5, 2010 · national
IN 4128CHE2012 · Nov 3, 2012 · national
IN 226CHE2013 · Jan 17, 2013 · national
Continuity (26)
Continuation In Part 15844459 · Dec 15, 2017
Continuation In Part 15689442 · Aug 29, 2017
Continuation In Part 15478013 · Apr 3, 2017
Continuation In Part 15288882 · Oct 7, 2016
Continuation In Part 14800950 · Jul 16, 2015
Continuation In Part 14698944 · Apr 29, 2015
Continuation In Part 14623608 · Feb 17, 2015
Continuation In Part 14520292 · Oct 21, 2014
Continuation 14476555 · Sep 3, 2014
Division 14206044 · Mar 12, 2014
Continuation PCTIN2014000031 · Jan 16, 2014
Division 14094725 · Dec 2, 2013
Continuation PCTIN2013000673 · Oct 31, 2013
Division 13674249 · Nov 12, 2012
Division 13645031 · Oct 4, 2012
Division 13506572 · Apr 30, 2012
Division 13385717 · Mar 5, 2012
Continuation In Part PCTIN2011000232 · Apr 4, 2011
Division 12926980 · Dec 21, 2010
Division 12926985 · Dec 21, 2010
Division 12662740 · Apr 30, 2010
Division 12073864 · Mar 11, 2008
Division 11635599 · Dec 8, 2006
Continuation PCTIN2005000176 · May 30, 2005
Provisional Application 61794175 · Mar 15, 2013
Related Publication 20200390727A1 · Dec 17, 2020